Autopsy report · NCT02265510
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Cause of deathNo reason given
Life of this trial
- Ran for about 4 years 6 months before it stopped.
- 83 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Incyte Corporation
- Sponsor type
- Industry
- Conditions
- Solid Tumors; Advanced Malignancies; Metastatic Cancer
- Interventions
- INCB052793; gemcitabine; nab-paclitaxel; dexamethasone; Carfilzomib; bortezomib
- Participants
- 83
- Sites
- 14
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.